Skip to content

Nexo Therapeutics

1 viewer · 30d

Total raised

$60.0M

1 filing since 2022 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $60.0M
ROUNDS
1
INVESTORS
7
FOUNDED
2022
HQ
Littleton, CO
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Nexo Therapeutics is a small-molecule oncology company founded in 2022 that discovers drugs against cancer targets historically considered undruggable. It applies covalent ligand discovery across all nucleophilic amino acids, combined with chemical biology, cancer biology and medicinal chemistry, to reach proteins that lack well-defined binding pockets. The company is headquartered in Littleton, Colorado with research laboratories in Watertown, Massachusetts, and raised a $60 million Series A from Versant Ventures, Cormorant Asset Management and New Enterprise Associates alongside a research alliance with The University of Texas MD Anderson Cancer Center.

What sets it apart

Covalent ligand discovery across all nucleophilic amino acids captures shallow, transient and otherwise intractable pockets, aiming at the roughly 80% of the proteome that conventional small-molecule drugs cannot reach.

Funding history

1 round
Equity+1Nov 15, 2022
Form D/A
+$60.0M$60.0M total

Latest SEC filings

via EDGAR · CIK 0001955319
Form D/A · Nov 15, 2022View on EDGAR

Products

1 tracked

Covalent ligand discovery platform

Oncology drug discovery platform

A drug discovery engine that pairs covalent chemistry across all nucleophilic amino acid residues with chemical biology and cancer biology to generate small-molecule candidates against targets without conventional binding pockets, including intrinsically disordered proteins, scaffolding proteins, transcription factors, paralogs and protein-protein interfaces.

  • Covalent ligand discovery across all nucleophilic amino acids
  • Targets intrinsically disordered proteins, scaffolding proteins and transcription factors
  • Captures shallow, challenging and transient binding pockets
  • Paralog-selective and protein-protein interface targeting